Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06712810 · ClinicalTrials.gov registry record · Phase 1

Q702 for the Treatment of Patients With Hematologic Malignancies

A Phase 1 study of Hematopoietic and Lymphatic System Neoplasm and Recurrent Chronic Lymphocytic Leukemia, sponsored by Mayo Clinic.

Recruiting
Registry status
Phase 1
Development phase
46
Enrollment target
2
Study locations

NCT06712810: Recruiting Phase 1 study of Hematopoietic and Lymphatic System Neoplasm and Recurrent Chronic Lymphocytic Leukemia, sponsored by Mayo Clinic.

NCT06712810 is a Phase 1 study of Hematopoietic and Lymphatic System Neoplasm and Recurrent Chronic Lymphocytic Leukemia that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 46 participants, below the 482-participant average among 62 other Hematopoietic and Lymphatic System Neoplasm trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06712810, a Phase 1 study of Hematopoietic and Lymphatic System Neoplasm and Recurrent Chronic Lymphocytic Leukemia, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
Phase 1
Development phase
46 participants
Enrollment target
2
Study locations

Study Summary

This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic malignancies.

Primary Outcome

Up to completion of the first cycle (cycle length= 28 days)

Conditions Studied

Hematopoietic and Lymphatic System Neoplasm Recurrent Chronic Lymphocytic Leukemia Recurrent Follicular Lymphoma Recurrent Chronic Myelomonocytic Leukemia Recurrent Langerhans Cell Histiocytosis Recurrent Lymphoplasmacytic Lymphoma Peripheral T-Cell Lymphoma, Not Otherwise Specified Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Histiocytic Sarcoma Malignant Histiocytosis

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Bone Marrow Aspiration
  • PROCEDURE Bone Marrow Biopsy
  • PROCEDURE Computed Tomography
  • DRUG Axl/Mer/CSF1R Inhibitor Q702

Study Locations (2)

Arizona

  • Mayo Clinic in Arizona - Scottsdale

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2025-08-27
Est. Completion 2030-09-15
Phase Phase 1
Mayo Clinic

2,844 total trials

What NCT06712810 shows while recruiting

NCT06712810 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 482-participant average among 62 other Hematopoietic and Lymphatic System Neoplasm trials with a reported enrollment target (90% lower).

The record links to 10 conditions, with Hematopoietic and Lymphatic System Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06712810 reports a single indexed study location in Arizona, Minnesota.

Frequently Asked Questions

What is clinical trial NCT06712810 about?

NCT06712810 is a clinical study titled "Q702 for the Treatment of Patients With Hematologic Malignancies". This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal bloo...

What is the current status of trial NCT06712810?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2025-08-27. Estimated completion is 2030-09-15.

What conditions does trial NCT06712810 study?

This clinical trial studies the following conditions: Hematopoietic and Lymphatic System Neoplasm, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Langerhans Cell Histiocytosis.

What interventions are being tested in trial NCT06712810?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Bone Marrow Aspiration (PROCEDURE), Bone Marrow Biopsy (PROCEDURE), Computed Tomography (PROCEDURE), Axl/Mer/CSF1R Inhibitor Q702 (DRUG).

Who is sponsoring clinical trial NCT06712810?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06712810 being conducted?

This trial has 2 study locations across Arizona, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hematopoietic and Lymphatic System Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06712810's enrollment target sits among peer trials

46 43rd of 62 higher than 20 of 62 other Hematopoietic and Lymphatic System Neoplasm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hematopoietic and Lymphatic System Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01890590 · 46 participants · NA

    A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma

  • NCT03191149 · 46 participants · Phase 2

    Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  • NCT03510208 · 46 participants · Phase 1

    Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

  • NCT04048278 · 46 participants · Early Phase 1

    Lidocaine Infusion in Pancreatic Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06712810

Source: ClinicalTrials.gov NCT06712810, the US trial registry maintained by the National Library of Medicine. NCT06712810 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.